title: The synthetic analogue of mycoplasmal lipoprotein FSL-1 induces dendritic cell maturation through Toll-like receptor 2.
abstract: Granulocyte-macrophage colony-stimulating factor-differentiated bone marrow-derived dendritic cells were stimulated with the synthetic lipopeptide S-(2,3-bispalmitoyloxypropyl)-CGDPKHSPKSF (FSL-1) or the Escherichia coli lipopolysaccharide. FSL-1 induced the production of TNF-alpha and IL-12 by C57BL/6-derived bone marrow-derived dendritic cells but not by bone marrow-derived dendritic cells from Toll-like receptor 2-deficient (TLR2(-/-)) mice. Lipopolysaccharide induced the production of TNF-alpha and IL-12 by bone marrow-derived dendritic cells derived from either type of mice. FSL-1 did not induce production of IL-10 by bone marrow-derived dendritic cells from either type of mice, whereas lipopolysaccharide induced small amounts of IL-10 by bone marrow-derived dendritic cells from both types of mice. The upregulation by FSL-1 of the expression of CD80, CD86 and the MHC class II molecule IA(b) was dose- and time-dependent on the surfaces of C57BL/6-derived bone marrow-derived dendritic cells but not on the surface of TLR2(-/-)-derived bone marrow-derived dendritic cells. Lipopolysaccharide upregulated the expression of these molecules on the surfaces of bone marrow-derived dendritic cells from both types of mice. The expression of CD11c on the surfaces of C57BL/6-derived bone marrow-derived dendritic cells was upregulated by stimulation with both FSL-1 and lipopolysaccharide up to 12 h; thereafter, the expression was downregulated. The results suggest that FSL-1 can accelerate maturation of bone marrow-derived dendritic cells and this FSL-1 activity is mediated by TLR2.
authors.affiliation: Department of Oral Pathobiological Science, Hokkaido University Graduate School of Dental Medicine, Nidhi 7, Kita 13, Kita-ku, Sapporo 060-8586, Japan.
authors.forename: Kazuto
authors.initials: K
authors.lastname: Kiura
authors.forename: Hideo
authors.initials: H
authors.lastname: Kataoka
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakata
authors.forename: Takeshi
authors.initials: T
authors.lastname: Into
authors.forename: Motoaki
authors.initials: M
authors.lastname: Yasuda
authors.forename: Shizuo
authors.initials: S
authors.lastname: Akira
authors.forename: Nobuo
authors.initials: N
authors.lastname: Inoue
authors.forename: Ken-ichiro
authors.initials: K
authors.lastname: Shibata
mesh_terms: D000818:Animals; D018122:B7-1 Antigen / Q000032:analysis / Q000378:metabolism; D051940:B7-2 Antigen / Q000032:analysis / Q000378:metabolism; D001854:Bone Marrow Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D004075:Diglycerides / Q000494:pharmacology*; D000949:Histocompatibility Antigens Class II / Q000032:analysis / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D051379:Mice; D008817:Mice, Mutant Strains; D009842:Oligopeptides / Q000494:pharmacology*; D018417:Th1 Cells / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation
chemical_list: D018122:B7-1 Antigen; D051940:B7-2 Antigen; D004075:Diglycerides; C460864:FSL-1 lipoprotein, synthetic; D000949:Histocompatibility Antigens Class II; D009842:Oligopeptides; D051195:Toll-Like Receptor 2; D018664:Interleukin-12